![](https://endpts.com/wp-content/uploads/2018/11/london-cloudy-endpts-tile.jpg)
In reversal, NICE backs Rubraca after Clovis agrees to a price cut
NICE has changed its mind, agreeing to cautiously endorse Clovis Oncology’s Rubraca after the drugmaker agreed to cut its price — about two months after the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.